Sparano Clotilde, Canu Letizia, Perigli Giuliano, Santoro Roberto, Pradella Silvia, Grazzini Giulia, Mangoni Monica, Simontacchi Gabriele, Fibbi Benedetta, Vezzosi Vania, Olianti Catia, Maggi Mario, Petrone Luisa
Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Endocrinology Unit, Careggi University Hospital, Florence, Italy.
Front Endocrinol (Lausanne). 2025 May 27;16:1513893. doi: 10.3389/fendo.2025.1513893. eCollection 2025.
The Endocrine Multidisciplinary Tumour Board (EMTB) is a specialised board for endocrine tumours, including thyroid, adrenal, and rare endocrine neoplasms. Although required by major guidelines, little is known about the current EMTB composition and working outcomes. The present study aims to analyse the use and support provided by an experienced EMTB, highlighting the skills of this board.
This monocentric and retrospective study considered all the cases discussed (N=1038, concerning 835 patients) within the ETMB of Careggi University Hospital of Florence from January 1st, 2021, to December 31st, 2023. The queries have been standardised into five major groups. Besides treatment and follow-up indications, particular attention has been paid to the need for repeated discussions, additional indications, imaging revisions, and overall survival (OS) outcomes.
Thyroid and rare cancers were the most frequently represented (64% and 32%, respectively). At logistic regression analysis, the need for multiple discussions was associated with being a rare disease (p<0.001), familiar syndrome (p=0.003), or adrenal masses (p=0.005). When the query was "imaging review," external imaging was more often re-evaluated (p=0.027) due to differing results at EMTB revision, and in about 51% of these cases, further insights were requested. Compared to external control groups, Anaplastic Thyroid Carcinoma and Adrenocortical Carcinoma showed improved OS, 7.84 vs 2.46 months (p=0.049) and 51.92 vs 26.17 months (p=0.0076), respectively. From the hormonal perspective, further hormonal investigations were required in about 16% of eligible cases.
EMTB is pivotal in managing and optimising common and rare endocrine tumour workups.
内分泌多学科肿瘤委员会（EMTB）是一个专门处理内分泌肿瘤的委员会，包括甲状腺、肾上腺和罕见内分泌肿瘤。尽管主要指南有要求，但目前对于EMTB的组成和工作成果知之甚少。本研究旨在分析一个经验丰富的EMTB的使用情况和提供的支持，突出该委员会的技能。
这项单中心回顾性研究纳入了佛罗伦萨卡雷吉大学医院EMTB在2021年1月1日至2023年12月31日期间讨论的所有病例（N = 1038，涉及835名患者）。问题被标准化分为五个主要组。除了治疗和随访指征外，还特别关注重复讨论的必要性、额外指征、影像学复查以及总生存期（OS）结果。
甲状腺癌和罕见癌症的病例占比最高（分别为64%和32%）。在逻辑回归分析中，需要多次讨论与罕见疾病（p < 0.001）、家族综合征（p = 0.003）或肾上腺肿块（p = 0.005）相关。当问题是“影像学复查”时，由于EMTB复查结果不同，外部影像学更常被重新评估（p = 0.027），并且在其中约51%的病例中，需要进一步的见解。与外部对照组相比，未分化甲状腺癌和肾上腺皮质癌的OS有所改善，分别为7.84个月对2.46个月（p = 0.049）和51.92个月对26.17个月（p = 0.0076）。从激素角度来看，约16%的符合条件的病例需要进一步的激素检查。
EMTB在管理和优化常见及罕见内分泌肿瘤检查方面起着关键作用。
